Platform for women with BRCA1 or BRCA2 mutations in Italy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter observational platform will prospectively register clinical, surgical, and follow-up data from adult women with pathogenic BRCA1 or BRCA2 mutations. Participants are recruited at several Italian oncology centers and data are entered into a centralized database to harmonize management and outcomes. The platform aims to generate real-world evidence on cancer risk, prevention strategies, and treatment patterns among BRCA carriers in Italy. Collected data can support more accurate risk estimates, inform national guidance, and identify candidates for preventive interventions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* All women who are 18 years of age or older;
* All women who known to be carriers of a pathogenetic mutation class 4 and 5 of the International Agency of Research on Cancer classification) of the BRCA1 or BRCA2 genes.

Exclusion Criteria:

* Age \< 18 years old;
* No pathogenetic mutation carriers.

Where it's running

• IRCCS Istituto Tumori "Giovanni Paolo II"
  Bari, Italy Recruiting
• Fondazione IRCCS San Gerardo dei Tintori
  Monza, Italy Recruiting
• Istituto Nazionale Tumori Fondazione G. Pascale
  Naples, Italy Recruiting
• Fondazione Policlinico Universitario Agostino Gemelli IRCCS, UOC Ginecologia Oncologica
  Rome, Italy Recruiting
• Malzoni Research Hospital
  Avellino, Italy Not yet recruiting
• Centro di Riferimento Oncologico IRCCS
  Aviano, Italy Not yet recruiting

Study contacts

• Principal investigator: Anna Fagotti — Fondazione Policlinico Universitario Agostino Gemelli IRCCS
• Study coordinator: Anna Fagotti
• Email: anna.fagotti@policlinicogemelli.it
• Phone: +390630157004

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Hormone replacement after risk-reducing salpingo-oophorectomy

  This trial will test whether adding a short educational video to usual counseling helps premenopausal people with BRCA1 or BRCA2 mutations who are planning risk-reducing salpingo-oophorectomy decide about hormone replacement therapy.

  Recruiting at 2 sites Duke University · Chapel Hill, North Carolina and 1 other locations · NCT06972719

• Testing axatilimab with olaparib for advanced HER2-negative breast cancer with specific gene mutations

  This study is testing a new drug called axatilimab combined with olaparib to see if it helps people with advanced HER2-negative breast cancer who have specific gene mutations.

  Recruiting at 2 sites Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06488378

• Testing a new drug ETX-19477 for advanced solid tumors

  This study is testing a new drug called ETX-19477 to see if it can help people with advanced solid tumors that haven't responded to other treatments.

  Recruiting at 14 sites Phase 1/2 858 Therapeutics, Inc. · Phoenix, Arizona and 13 other locations · NCT06395519

• Combining Elacestrant with Olaparib for Advanced Breast Cancer Treatment

  This study is testing if adding elacestrant to olaparib can help people with advanced breast cancer who have specific genetic mutations live longer without their cancer getting worse.

  Recruiting at 35 sites Phase 2 GBG Forschungs GmbH · Stuttgart, Baden-Wurttemberg and 35 other locations · NCT06201234

• Combining niraparib and irinotecan for cancers with DNA repair gene mutations

  This study is testing a new combination of two cancer drugs, niraparib and irinotecan, to see if it's safe and effective for people with certain types of cancer that have DNA repair gene mutations.

  Recruiting Phase 1 University of California, San Francisco · San Francisco, California · NCT05694715

• New treatment approach for BRCA1/2 mutated triple negative breast cancer

  This study is testing a new treatment combining Olaparib and Pembrolizumab for people with BRCA1/2 mutated triple negative breast cancer to see if it works better after chemotherapy.

  Recruiting at 3 sites Phase 2 Okayama University · Gifu, Gifu and 2 other locations · NCT05485766

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.